- Report
- April 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2023
- 85 Pages
Middle East, Africa
From €1448EUR$1,500USD£1,242GBP
- Report
- April 2023
- 156 Pages
Global
€4826EUR$5,000USD£4,140GBP
- Report
- April 2023
- 114 Pages
Global
€3378EUR$3,500USD£2,898GBP
Atrovent is a brand name for the drug ipratropium bromide, a bronchodilator used to treat chronic obstructive pulmonary disease (COPD) and asthma. It is a long-acting anticholinergic drug that works by relaxing the muscles in the airways, allowing air to flow more freely. It is available in both an inhaler and a nebulizer solution. Atrovent is often used in combination with other respiratory drugs, such as corticosteroids and beta-agonists, to provide more effective relief from symptoms.
Atrovent is one of the most commonly prescribed respiratory drugs in the world. It is used to treat a wide range of respiratory conditions, including COPD, asthma, and bronchitis. It is also used to prevent bronchospasm in people with COPD who are exposed to certain triggers, such as smoke or dust.
The Atrovent market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include GlaxoSmithKline, Boehringer Ingelheim, Merck, and Teva Pharmaceuticals. Show Less Read more